文献速递MDS 与骨髓增殖性肿瘤

伴NFE2基因突变的骨髓增殖性肿瘤临床与分子特征

[Clinical and molecular characteristics of myeloproliferative neoplasms patients with NFE2 gene mutations].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

该回顾性研究对723例MPNs患者进行靶向测序,检出41例(5.7%)NFE2基因突变,以移码突变为主。NFE2突变与年龄较大、诊断前血栓史及多个炎症因子升高相关,且多为亚克隆晚期事件。PV和ET伴NFE2突变者高危预后分组比例更高,但总生存和累积血栓发生率无显著差异。

要点

  • MPNs中NFE2突变率5.7%,以移码突变(44.4%)最常见。
  • NFE2突变与年龄大、诊断前血栓史及炎症因子升高独立相关。
  • NFE2突变多为亚克隆事件,80.5%发生在驱动突变之后。

核心结论

  • MPNs中NFE2基因突变多为移码突变。
  • NFE2突变与年龄较大及多个炎症因子水平升高相关,且多为疾病晚期出现的分子异常。

研究设计与样本

  • 回顾性分析2021年4月至2023年6月中国医学科学院血液病医院723例MPNs患者。
  • 采用血液肿瘤相关基因靶向二代测序检测NFE2基因突变。

主要发现

  • 723例中41例(5.7%)检出NFE2突变,移码突变44.4%、无义突变33.3%。
  • NFE2突变组中位基因突变个数4(2,5)个,高于无突变组2(1,3)个(P<0.001)。
  • NFE2突变常与MPL、ATM、PPM1D、TET1共突变,80.5%发生在驱动突变后。
  • NFE2突变组年龄更大[60(54,67)岁对54(41,63)岁,P=0.001],诊断前血栓史39.0%对22.0%(P=0.012),动脉血栓史36.6%对20.4%(P=0.014)。
  • 校正年龄和合并症后,NFE2突变是TNF-α(OR=2.747,95%CI:1.143~6.605,P=0.024)、IFN-γ(OR=2.689,95%CI:1.191~6.076,P=0.017)、IL-10(OR=3.219,95%CI:1.343~7.717,P=0.009)、IL-12P70(OR=3.397,95%CI:1.003~11.508,P=0.049)、IL-17(OR=2.284,95%CI:1.017~5.127,P=0.045)升高的独立影响因素。

关键数值与推荐

  • PV伴NFE2突变者IWG-PV高危比例66.7%对25.3%(P=0.033),MIPSS-PV高危比例22.2%对2.0%(P=0.013)。
  • ET伴NFE2突变者MIPSS-ET高危比例15.4%对6.1%(P=0.021)。
  • NFE2突变组(38例)与无突变组(671例)总生存和累积血栓发生率差异均无统计学意义(均P>0.05)。

临床怎么用

  • 对MPNs患者可行NFE2基因检测以辅助识别高危亚组。
  • 伴NFE2突变者应关注血栓病史及炎症因子水平。

局限性

  • 回顾性单中心研究,样本量有限。
  • NFE2突变组仅41例,生存和血栓分析样本更少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the clinical features and molecular characteristics of myeloproliferative neoplasms (MPNs) patients with NFE2 gene mutations. Methods: Gene targeted sequencing was used to detect NFE2 gene mutation in 723 patients diagnosed with MPNs who were admitted to Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College between April 2021 and June 2023. The association between NFE2 gene mutations and clinical features and molecular characteristics of MPNs patients were retrospectively analyzed. Results: Among 723 patients with MPNs, NFE2 gene mutations were found in 41 cases (5.7%) . NFE2 gene mutations were predominantly frameshift mutations (44.4%) , followed by nonsense mutations (33.3%) . The median number of mutations in patients with NFE2 gene mutations (4 [2,5]) was higher compared to the group without NFE2 gene mutations (2, [1,3]) (P<0.001) . NFE2 gene mutations frequently co-occurred with mutations in MPL, ATM, PPM1D, and TET1. NFE2 gene mutations were mostly sub-clonal events, with 80.5% occurring after MPNs driver mutations (JAK2, CALR, or MPL) . NFE2 mutations were correlated with older age [median age: 60 (54, 67) years vs 54 (41, 63) years, P=0.001]. Patients with NFE2 gene mutations had a higher incidence of pre-diagnosis thrombosis (39.0% vs 22.0%, P=0.012) and pre-diagnosis arterial thrombosis (36.6% vs 20.4%, P=0.014) . Using a logistic regression analysis model adjusting for age and comorbidities (including chronic infections, malignancies, and autoimmune diseases) , NFE2 gene mutation was identified as an independent determinant of elevated tumor necrosis factor-alpha (TNF-α) (OR=2.747, 95%CI: 1.143-6.605, P=0.024) , interferon-gamma (IFN-γ) (OR=2.689, 95%CI: 1.191-6.076, P=0.017) , IL-10 (OR=3.219, 95% CI: 1.343-7.717, P=0.009) , IL-12P70 (OR=3.397, 95%CI:1.003-11.508, P=0.049) , IL-17 (OR=2.284, 95%CI: 1.017-5.127, P=0.045) . In polycythaemia vera (PV) patients with the NFE2 gene mutation, the proportion of those classified as high-risk is notably higher in both the IWG-PV and mutation-enhanced international prognostic systems for PV (MIPSS-PV) (66.7% vs 25.3% for IWG-PV, P=0.033; 22.2% vs 2.0% for MIPSS-PV, P=0.013) . Similarly, for essential thrombocythaemia (ET) patients, the proportion in the high-risk group of the mutation-enhanced international prognostic systems for ET (MIPSS-ET) is significantly higher (15.4% vs 6.1%, P=0.021) . No statistically significant differences were observed in overall survival or cumulative incidence of thrombosis between NFE2-mutated (38 cases) and non-mutated MPNs patients (671 cases, P>0.05) . Conclusion: NFE2 gene mutations in MPNs were predominantly frameshift mutations. NFE2 gene mutations were correlated with older age, elevated levels of several inflammatory factors (including TNF-α、IFN-γ、IL-10、IL-12P70、IL-17) , and they mostly occurred in late-stage of MPNs. 目的: 探讨伴NFE2基因突变的骨髓增殖性肿瘤(MPNs)患者的临床和分子生物学特征。 方法: 回顾性分析2021年4月至2023年6月期间就诊于中国医学科学院血液病医院接受血液肿瘤相关基因靶向二代基因测序的723例MPNs患者临床和实验室资料,分析伴NFE2基因突变患者的临床和分子生物学特征。 结果: 723例MPNs患者中,41例(5.7%)患者检出NFE2基因突变,NFE2基因突变中移码突变最常见(44.4%),其次是无义突变(33.3%)。NFE2基因突变组患者中位基因突变个数多于无NFE2基因突变组[4(2,5)个对2(1,3)个,P<0.001]。NFE2基因突变常与MPL、ATM、PPM1D、TET1基因突变共同发生。NFE2基因突变多为亚克隆突变,80.5%在MPNs驱动突变(JAK2、CALR、MPL)后发生。与无NFE2基因突变组比较,NFE2基因突变组年龄大[中位年龄:60(54,67)岁对54(41,63)岁,P=0.001],诊断前血栓病史(39.0%对22.0%,P=0.012)、诊断前动脉血栓病史患者比例(36.6%对20.4%,P=0.014)高。利用Logistic回归分析模型,校正年龄、合并症(慢性感染、肿瘤、自身免疫性疾病)后结果显示NFE2基因突变是TNF-α(OR=2.747,95% CI:1.143~6.605,P=0.024)、γ干扰素(IFN-γ)(OR=2.689,95%CI:1.191~6.076,P=0.017)、IL-10(OR=3.219,95%CI:1.343~7.717, P=0.009)、IL-12P70(OR=3.397,95%CI:1.003~11.508,P=0.049)、IL-17(OR=2.284,95%CI:1.017~5.127,P=0.045)增高的独立影响因素。NFE2基因突变的真性红细胞增多症(PV)患者中国际工作组PV预后积分系统(IWG-PV)和包含基因突变的PV预后积分系统(MIPSS-PV)高危患者比例高(IWG-PV:66.7%对25.3%,P=0.033;MIPSS-PV:22.2%对2.0%,P=0.013);原发性血小板增多症(ET)患者中MIPSS-ET高危患者比例高(15.4%对6.1%,P=0.021)。NFE2基因突变(38例)和无NFE2基因突变组(671例)MPNs患者总生存期和累计血栓发生率差异均无统计学意义(均P>0.05)。 结论: MPNs中NFE2基因突变多为移码突变。NFE2基因突变与MPNs患者年龄较大、多个炎症因子(TNF-α、IFN-γ、IL-10、IL-12P70、IL-17)水平升高相关,且多为MPNs疾病晚期出现的分子生物学异常改变。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhao SY, Li B, Xu ZF, et al. [Clinical and molecular characteristics of myeloproliferative neoplasms patients with NFE2 gene mutations]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41339048. doi:10.3760/cma.j.cn121090-20241214-00569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。